GHRP1
GHRP-1, GHRP1.
Greater than 97.0% as determined by analysis by RP-HPLC.
Description
Growth Hormone Releasing Peptide-1 Synthetic is a single, non-glycosylated polypeptide chain containing 5 amino acids, having a molecular mass of 955.11 Dalton and a Molecular formula of C51H62N12O7.
Product Specs
Growth hormone-releasing peptides (GHRPs) are a class of synthetic peptides that act on pituitary somatotrophs to stimulate the release of growth hormone (GH), similar to the naturally occurring growth hormone-releasing hormone (GHRH). GHRP-1, a specific type of GHRP, is derived from the peptide met-enkephalin but incorporates unnatural D-amino acids. Initially developed for their GH-releasing properties, GHRPs are often referred to as GH secretagogues. While they do not exhibit opioid activity, they potently promote GH secretion. Importantly, GHRPs differ from GHRH in their amino acid sequence and their mechanism of action, as they exert their effects by binding to a distinct receptor known as the ghrelin receptor.
Synthetic growth hormone-releasing peptide-1 is a single-chain polypeptide consisting of 5 amino acids. It is not glycosylated and has a molecular weight of 955.11 Daltons. Its molecular formula is C51H62N12O7.
The peptide is provided in a lyophilized form without any additional ingredients.
To reconstitute lyophilized GHRP-1, it is recommended to dissolve it in sterile 18MΩ-cm H2O at a concentration of at least 100 µg/ml. The resulting solution can be further diluted using other aqueous solutions as needed.
Lyophilized GHRP-1 remains stable for up to 3 weeks at room temperature. However, for long-term storage, it is advisable to store the lyophilized powder in a dry environment below -18°C. Once reconstituted, GHRP-1 should be stored at 4°C for a period of 2 to 7 days. For extended storage after reconstitution, freezing at -18°C is recommended, preferably with the addition of a carrier protein like HSA or BSA at a concentration of 0.1%. To maintain the integrity of the peptide, avoid repeated cycles of freezing and thawing.
The purity of the product is greater than 97.0%, as determined by reverse-phase high-performance liquid chromatography (RP-HPLC) analysis.
GHRP-1, GHRP1.
Ala-His-(D-β-Nal)-Ala-Trp-(D-Phe)-Lys-NH2.
Product Science Overview
Growth Hormone Releasing Peptide-1 (GHRP-1) is a synthetic peptide that stimulates the secretion of growth hormone (GH) from the pituitary gland. Unlike Growth Hormone-Releasing Hormone (GHRH), which is a naturally occurring hormone, GHRP-1 is a non-natural peptide designed to mimic the effects of GHRH but with distinct structural and functional properties .
The concept of growth hormone-releasing peptides (GHRPs) emerged in the late 20th century as researchers sought to develop synthetic analogs that could effectively stimulate GH release. GHRP-1 was one of the first peptides in this class to be synthesized and studied. It was developed through a series of experiments aimed at identifying compounds that could bind to specific receptors in the hypothalamus and pituitary gland, thereby triggering the release of GH .
GHRP-1 acts by binding to the growth hormone secretagogue receptor (GHS-R) present in the hypothalamus and pituitary gland. This binding stimulates the release of GH in a pulsatile manner, similar to the natural secretion pattern of GH in the body. The peptide does not have structural homology with GHRH, indicating that it operates through a different receptor and signaling pathway .
The primary effect of GHRP-1 is the stimulation of GH release, which in turn promotes various physiological processes such as growth, metabolism, and tissue repair. GH plays a crucial role in regulating body composition, muscle and bone growth, and overall metabolic health. By enhancing GH secretion, GHRP-1 can potentially improve these physiological functions .
GHRP-1 and other GHRPs have been investigated for their potential therapeutic applications in conditions characterized by GH deficiency or insufficiency. These conditions include growth hormone deficiency in children and adults, cachexia (muscle wasting) associated with chronic diseases, and age-related decline in GH levels. Clinical studies have shown that GHRP-1 can effectively increase GH levels and improve related clinical outcomes .
The safety profile of GHRP-1 has been evaluated in various clinical trials. Common side effects include transient increases in cortisol and prolactin levels, which are generally well-tolerated. Long-term safety data are still limited, and further research is needed to fully understand the potential risks and benefits of GHRP-1 therapy .
